Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.

Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A.

Parkinsonism Relat Disord. 2005 May;11(3):151-5.

PMID:
15823479
2.

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L; Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease.

Mov Disord. 2004 Sep;19(9):1020-8.

PMID:
15372591
3.

Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.

Gluck MR, Santana LA, Granson H, Yahr MD.

J Neural Transm (Vienna). 2004 Jun;111(6):713-24. Epub 2004 Apr 8.

PMID:
15168218
4.

Norepinephrine precursor therapy in neurogenic orthostatic hypotension.

Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.

Circulation. 2003 Aug 12;108(6):724-8. Epub 2003 Jul 28.

PMID:
12885750
5.

Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings.

Yahr MD, Orosz D, Purohit DP.

Parkinsonism Relat Disord. 2003 Mar;9(4):225-31.

PMID:
12618058
6.

Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.

Bhattacharya KF, Nouri S, Olanow CW, Yahr MD, Kaufmann H.

Parkinsonism Relat Disord. 2003 Mar;9(4):221-4.

PMID:
12618057
7.

Gerald Cohen 1930-2001.

Yahr MD.

Parkinsonism Relat Disord. 2002 Sep;8(6):381-4. No abstract available.

PMID:
12356024
8.

Intrastriatal iron perfusion releases dopamine: an in-vivo microdialysis study.

Prikhojan A, Brannan T, Yahr MD.

J Neural Transm (Vienna). 2002 May;109(5-6):645-9.

PMID:
12111456
9.

Parkinsonism: onset, progression, and mortality. 1967.

Hoehn MM, Yahr MD.

Neurology. 2001 Nov;57(10 Suppl 3):S11-26. No abstract available.

PMID:
11775596
10.

COMT-dependent protection of dopaminergic neurons by methionine, dimethionine and S-adenosylmethionine (SAM) against L-dopa toxicity in vitro.

Werner P, Di Rocco A, Prikhojan A, Rempel N, Bottiglieri T, Bressman S, Yahr MD.

Brain Res. 2001 Mar 2;893(1-2):278-81.

PMID:
11223018
11.

Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.

Prikhojan A, Brannan T, Yahr MD.

J Neural Transm (Vienna). 2000;107(10):1159-64.

PMID:
11129105
12.

Focal tremor following striatal infarct--a case report.

Brannan T, Yahr MD.

Mov Disord. 1999 Mar;14(2):368-70. No abstract available.

PMID:
10091639
13.

Postencephalitic parkinsonism--a review.

Casals J, Elizan TS, Yahr MD.

J Neural Transm (Vienna). 1998;105(6-7):645-76. Review.

PMID:
9826109
14.

Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism.

Di Rocco A, Brannan T, Prikhojan A, Yahr MD.

J Neural Transm (Vienna). 1998;105(2-3):247-51.

PMID:
9660102
15.
16.

Parkinsonism: onset, progression, and mortality. 1967.

Hoehn MM, Yahr MD.

Neurology. 1998 Feb;50(2):318 and 16 pages following. No abstract available.

PMID:
9484345
17.
18.

Editorial.

Yahr MD.

Parkinsonism Relat Disord. 1996 Jul;2(3):123-4. No abstract available.

PMID:
18591028
20.
21.

The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning.

Tagliati M, Bodis-Wollner I, Yahr MD.

Electroencephalogr Clin Neurophysiol. 1996 Jan;100(1):1-11.

PMID:
8964257
22.

An unusual sphenoid ridge tumor: cementifying fibroma.

Molinari SP, Di Rocco A, Merchant C, Sen CN, Wolfe D, Yahr MD.

J Neurol. 1996 Jan;243(1):103-4. No abstract available.

PMID:
8869398
23.

Parkinson's disease: progression and mortality in the L-DOPA era.

Di Rocco A, Molinari SP, Kollmeier B, Yahr MD.

Adv Neurol. 1996;69:3-11. No abstract available.

PMID:
8615142
24.

Central neurocytoma: An unusual intraventricular tumor.

Molinari SP, Sivakumar K, Corbin D, Yahr MD.

Mt Sinai J Med. 1995 Nov;62(6):436-8.

PMID:
8692158
25.

In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.

Brannan T, Prikhojan A, Martínez-Tica J, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1995;10(2-3):79-89.

PMID:
9620056
26.

The use of famotidine in the treatment of Parkinson's disease: a pilot study.

Molinari SP, Kaminski R, Di Rocco A, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1995;9(2-3):243-7.

PMID:
8527008
27.

Human transplacental transfer of carbidopa/levodopa.

Merchant CA, Cohen G, Mytilineou C, DiRocco A, Moros D, Molinari S, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1995;9(2-3):239-42.

PMID:
8527007
28.

Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease.

Bodis-Wollner I, Borod JC, Cicero B, Haywood CS, Raskin S, Mylin L, Sliwinski M, Falk A, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1995;9(2-3):197-209.

PMID:
8527004
30.

Impaired oxidation of pyruvate in human embryonic fibroblasts after exposure to L-dopa.

Werner P, Mytilineou C, Cohen G, Yahr MD.

Eur J Pharmacol. 1994 Sep 22;263(1-2):157-62.

PMID:
7821347
31.

Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: an in vivo study.

Brannan T, Prikhojan A, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1994;8(1-2):99-105.

PMID:
7893380
32.

Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease.

Mytilineou C, Werner P, Molinari S, Di Rocco A, Cohen G, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1994;8(3):223-8.

PMID:
7748465
33.

Parkinson's disease. The L-dopa era.

Yahr MD.

Adv Neurol. 1993;60:11-7. Review. No abstract available.

PMID:
8420128
34.

Parkinson's disease: new approaches to diagnosis and treatment.

Yahr MD.

Acta Neurol Scand Suppl. 1993;146:22-5. Review.

PMID:
8333251
35.

MRI abnormalities in Creutzfeldt-Jakob disease.

Di Rocco A, Molinari S, Stollman AL, Decker A, Yahr MD.

Neuroradiology. 1993;35(8):584-5.

PMID:
8278035
36.

Effect of repeated electroconvulsive shock on striatal L-dopa and dopamine metabolism: an in vivo study.

Brannan T, Martínez-Tica J, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1993;6(1):35-44.

PMID:
7692872
37.

Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study.

Brannan T, Martínez-Tica J, Di Rocco A, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1993;6(2):81-7.

PMID:
7509606
38.

Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.

Brannan T, Martínez-Tica J, Yahr MD.

Neurology. 1992 Mar;42(3 Pt 1):683-5.

PMID:
1549240
39.

Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure.

Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD.

Neurology. 1992 Mar;42(3 Pt 1):590-3.

PMID:
1549219
40.

Changes in body temperature markedly affect striatal dopamine release and metabolism: an in vivo study.

Brannan T, Martínez-Tica J, Yahr MD.

J Neural Transm Gen Sect. 1992;89(3):193-6.

PMID:
1389003
41.

Effect of dietary protein on striatal dopamine formation following L-dopa administration: an in vivo study.

Brannan T, Martinez-Tica J, Yahr MD.

Neuropharmacology. 1991 Oct;30(10):1125-7.

PMID:
1758587
42.

Effect of long-term L-dopa administration on striatal extracellular dopamine release.

Brannan T, Martinez-Tica J, Yahr MD.

Neurology. 1991 Apr;41(4):596-8.

PMID:
2011263
43.
45.

Effect of yohimbine on brain monoamines: an in vivo study.

Brannan T, Martinez-Tica J, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1991;3(2):81-7.

PMID:
1716906
46.

Lewy bodies in parkinsonism share components with intraneuronal protein bodies of normal brains.

Issidorides MR, Mytilineou C, Panayotacopoulou MT, Yahr MD.

J Neural Transm Park Dis Dement Sect. 1991;3(1):49-61.

PMID:
1712207
47.

Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep.

Askenasy JJ, Yahr MD.

J Neurol Neurosurg Psychiatry. 1990 Sep;53(9):749-53.

48.

Atrial natriuretic factor in human autonomic failure.

Kaufmann H, Oribe E, Pierotti AR, Roberts JL, Yahr MD.

Neurology. 1990 Jul;40(7):1115-9.

PMID:
2141387
49.

L-threodops increases extracellular norepinephrine levels in the brain: an in vivo study.

Brannan T, Bhardwaj A, Yahr MD.

Neurology. 1990 Jul;40(7):1134-5.

PMID:
2113206
50.

Visuospatial orientation in Parkinson's disease.

Raskin SA, Borod JC, Wasserstein J, Bodis-Wollner I, Coscia L, Yahr MD.

Int J Neurosci. 1990 Mar;51(1-2):9-18.

PMID:
2265914

Supplemental Content

Support Center